autologous enhanced NY-ESO-1 TCR engineered T cells GSK4427296

A preparation of human autologous engineered T lymphocytes that express an affinity-enhanced T-cell receptor (TCR) specific for the cancer-testis antigen 1 (NY-ESO-1; New York esophageal antigen-1), with potential immunostimulating and antineoplastic activities. Upon administration, autologous enhanced NY-ESO-1 TCR engineered T cells GSK4427296 recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA) and member of the cancer-testis antigen (CTA) family, is found in normal testis and on the surface of various tumor cell types, and is not, or is minimally, expressed in normal, healthy cells. The TCR T cells are manufactured and expanded using specific epigenetic reprogramming (Epi-R) technology with continuous NY-ESO-1 antigen exposure and stimulation to alter the phenotypic T-cell profile. This allows for the creation of more CD8-positive stem-like T cells, thereby increasing stemness properties which could potentially improve T-cell function, and increase T-cell proliferation, functional persistence, metabolic fitness, self-renewal, and enhance durable anti-tumor responses.